# Pizarra — PT-pseudo_3477ea7065bd (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3477ea7065bd
Task: 1

Encounter: Urology - outpatient on 08 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 13.9 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.177 ng/mL²
  - PSA velocity: 1.41 ng/mL/yr
  - Prior PSA: 11.7 ng/mL
  - Prostate volume: 78.69 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.5224143 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 13.9 ng/mL. PI-RADS 4. PSAD 0.18. Prostate volume 79 mL. csPCa 0.52.

Vitals: weight 77 kg, height 186 cm, BMI 22.3, BP 119/82 mmHg, HR 70 bpm. Smoking: Ex-smoker (33 pack-yr, quit 2019).

Chief complaint: Persistent elevation in prostate-specific antigen values alongside newly acquired multiparametric magnetic resonance imaging results warrant clinical assessment.

History: At age 65, this retired butcher recently moved into his sister’s residence half a year ago. Initial investigation into an early 2023 prostate-specific antigen elevation revealed a continuous two-year ascent, culminating in a current value of 13.9 ng/mL. Voiding difficulties remain bothersome, registering an IPSS score of 22. Tobacco use ceased in 2019 after a cumulative exposure of 33 pack-years. Physical activity includes cycling roughly 20 kilometres twice weekly, with alcohol intake limited to four units per week. Medical background remains clear of comorbidities: none. Active medication: None. Past surgical history includes a radical prostatectomy completed six years prior and a routine knee arthroscopy five years back, alongside uncomplicated biannual dental visits. Mild vision loss is managed through large-print correspondence requests. Sleep patterns and weight remain stable. Following a divorce and his recent relocation, practical assistance is provided by his sister. Prior biopsy bucket: None.

Physical examination: DRE — consistency: smooth and firm; symmetry: balanced enlargement without discrete nodules or focal irregularities. Vital parameters remain stable at 119/82 mmHg with a regular cardiac rhythm of 70 beats per minute. Systemic survey reveals no abdominal masses or peripheral lymphadenopathy.

Patient info: retired butcher; Divorced; Recently relocated; lives with sister.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 4 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 22/35 (severe LUTS).

Recent other appointments: Dental — biannual check-up.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.79 +/- 0.06   (95% CI 0.68-0.91)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.06  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.73 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI report detail the lesion size, zone, and comparison against earlier studies?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend and velocity beyond the headline value of 13.9 ng/mL?
  - previous_notes (get_previous_notes) -> What is the prior management context, including prior grade and surveillance pathway?

This case hinges on integrating the PI-RADS 4 finding with the clinical context (biopsy-naive status) and the trajectory of the PSA. The decision requires evidence from the retrieved documents to confirm the protocol's recommendation. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical model only considered the structured panel, which excluded the prose of the mpMRI report, the PSA trajectory, and the previous notes. Specifically, it did not weigh the high PSA velocity (1.41 ng/mL/yr) or the specific PI-RADS 4 score against the biopsy-naive status. It also did not account for the clinical context of the patient's prior radical prostatectomy six years ago.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a high probability (0.79). This suggestion could be wrong because the guideline criterion is to defer biopsy when PI-RADS is 1-2, and the patient has a PI-RADS 4, which is a strong indication for biopsy according to the protocol. The prior might be over-weighting the PI-RADS 4 without adequately factoring in the patient's history, such as the prior radical prostatectomy, which might alter the risk profile.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI report detail the lesion size, zone, and comparison against earlier studies?
psa_trend - What is the serial PSA trend and velocity beyond the headline value of 13.9 ng/mL?
previous_notes - What is the prior management context, including prior grade and surveillance pathway?
previous_notes - What is the prior management context, including prior grade and surveillance pathway?

GUIDELINE ANCHOR
The guideline states that biopsy is indicated when the mpMRI shows a PI-RADS 3 or higher lesion.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: Focal lesion in the right peripheral zone, 12 x 10 mm, PI-RADS 4. No extraprostatic extension or seminal vesicle invasion.
get_psa_trend
PSA trend: PSA rose from 2.9 ng/mL (Jan 2023) to 13.9 ng/mL (Jan 2025). Velocity is significant.
get_previous_notes
Previous notes: Last assessment on 10 Sep 2024 noted a steady upward trajectory from 10.1 ng/mL to 11.7 ng/mL, leading to the current consultation. No prior biopsy grade was documented.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and no new laboratory questions arose from the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI shows a PI-RADS 4 lesion in the right mid-peripheral zone.
- PSA trend shows a significant upward trajectory, reaching 13.9 ng/mL.
- Previous notes confirm a history of rising PSA and LUTS, necessitating the current workup.

AGAINST sampling this patient now:
- Previous notes do not document a prior biopsy grade, which is a characterisation problem.

WHERE THIS LEANS
The evidence strongly supports proceeding with a biopsy due to the PI-RADS 4 finding and the concerning PSA velocity, aligning with the EXPERT-PROTOCOL's criterion.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (PI-RADS 4 lesion, significant PSA trend, and history of rising PSA without prior biopsy grade) strongly supports the EXPERT-PROTOCOL's recommendation for biopsy.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across all inputs. The EXPERT-PROTOCOL criterion mandates biopsy for a PI-RADS 4 lesion, which was confirmed by the retrieved radiology report. This was further supported by the significant PSA trend, rising from 2.9 ng/mL to 13.9 ng/mL, which aligns with the statistical prior's suggestion. The PI-RADS 4 finding was the decisive factor that confirmed the protocol's recommendation.

Variables that carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
